Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMG901 + ivonescimab
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CMG901 + ivonescimab is an investigational combination regimen being evaluated for the treatment of gastrointestinal (GI) cancers, including gastric and gastroesophageal junction cancers. The combination pairs sonesitatug vedotin (CMG901/AZD0901), a first-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2) conjugated to a cytotoxic monomethyl auristatin E (MMAE) payload, with ivonescimab, a first-in-class bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). Developed under a clinical collaboration between AstraZeneca and Summit Therapeutics, this combination aims to synergize targeted tumor cell killing, immune checkpoint blockade, and anti-angiogenesis to improve therapeutic outcomes in patients with advanced GI malignancies.
- Other names
- AZD0901 + AK112AZD0901 + ivonescimabCMG901 + AK112sone-ve + ivonescimabsonesitatug vedotin + AK112sonesitatug vedotin + ivonescimab
02
Targets
Claudin 18.2PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on CMG901 + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMG901 + ivonescimab.